CHRS vs DUOT Comparison

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.